Title |
Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis
|
---|---|
Published in |
Retrovirology, May 2013
|
DOI | 10.1186/1742-4690-10-51 |
Pubmed ID | |
Authors |
Mineki Saito, Reiko Tanaka, Shiho Arishima, Toshio Matsuzaki, Satoshi Ishihara, Takashi Tokashiki, Yusuke Ohya, Hiroshi Takashima, Fujio Umehara, Shuji Izumo, Yuetsu Tanaka |
Abstract |
OX40 is a member of the tumor necrosis factor receptor family that is expressed primarily on activated CD4+ T cells and promotes the development of effector and memory T cells. Although OX40 has been reported to be a target gene of human T-cell leukemia virus type-1 (HTLV-1) viral transactivator Tax and is overexpressed in vivo in adult T-cell leukemia (ATL) cells, an association between OX40 and HTLV-1-associated inflammatory disorders, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), has not yet been established. Moreover, because abrogation of OX40 signals ameliorates chronic inflammation in animal models of autoimmune disease, novel monoclonal antibodies against OX40 may offer a potential treatment for HTLV-1-associated diseases such as ATL and HAM/TSP. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
United States | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 2% |
Brazil | 1 | 2% |
Unknown | 45 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 17% |
Researcher | 7 | 15% |
Student > Postgraduate | 4 | 9% |
Student > Bachelor | 3 | 6% |
Student > Doctoral Student | 3 | 6% |
Other | 9 | 19% |
Unknown | 13 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 30% |
Agricultural and Biological Sciences | 7 | 15% |
Immunology and Microbiology | 6 | 13% |
Neuroscience | 2 | 4% |
Engineering | 2 | 4% |
Other | 2 | 4% |
Unknown | 14 | 30% |